Literature DB >> 26054690

miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor.

Renxiong Wei1, Zhouming Deng2, Jiajia Su3.   

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults, however roles of microRNAs (miRNAs) in OS is still unclear. miR-217 is recently widely studied in various cancers, but not including OS. This study is aimed to investigate the expression and cellular function of miR-217 in OS. The data showed that miR-217 expression was consistently lower in OS tissues and cell lines than the normal controls. Restoration of miR-217 expression in MG-63 and U2OS cells could inhibit cell proliferation, migration and invasion, and induced apoptosis. Bioinformatic prediction suggested that Wnt5a is a target gene of miR-217. Using luciferase assay, mRNA and protein expression analysis, it was verified that Wnt5a was a target gene of miR-217 in OS cells. Restored expression of Wnt5a weakened miR-217-mediated suppression of tumor progression. Taken together, our data indicate that miR-217 functions as a tumor suppressor in OS by suppressing Wnt5a expression.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Osteosarcoma; Tumor progression; Wnt5a; miR-217

Mesh:

Substances:

Year:  2015        PMID: 26054690     DOI: 10.1016/j.biopha.2015.04.012

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  Baicalin augments the differentiation of osteoblasts via enhancement of microRNA-217.

Authors:  Qi Wang; Donglei Shi; Yuanyuan Geng; Qishan Huang; Longzhan Xiang
Journal:  Mol Cell Biochem       Date:  2019-10-12       Impact factor: 3.396

3.  MiR-217 promotes cutaneous squamous cell carcinoma progression by targeting PTRF.

Authors:  Ming Bai; Mingzi Zhang; Fei Long; Nanze Yu; Ang Zeng; Xiaojun Wang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS.

Authors:  Yi Xiao; Taoran Deng; Changliang Su; Zhen Shang
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

5.  MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1.

Authors:  Yang Qu; Su Pan; Mingyang Kang; Rongpeng Dong; Jianwu Zhao
Journal:  Tumour Biol       Date:  2015-11-11

6.  MicroRNA-217 inhibits cell proliferation and invasion by targeting Runx2 in human glioma.

Authors:  Yonggang Zhu; Hongguang Zhao; Li Feng; Songbai Xu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

7.  ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a.

Authors:  Bin Dai; Ting Yan; Ailiang Zhang
Journal:  Cancer Cell Int       Date:  2017-11-29       Impact factor: 5.722

8.  MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A.

Authors:  Meiyue Liu; Yue Zhang; Jie Zhang; Haifeng Cai; Chao Zhang; Zhao Yang; Yi Niu; Huan Wang; Xiaomei Wei; Wei Wang; Peng Gao; Hongmin Li; Jinghua Zhang; Guogui Sun
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

9.  miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.

Authors:  Wenhui Zhou; Fangfang Song; Qiuju Wu; Rong Liu; Lulu Wang; Cuicui Liu; You Peng; Shuqin Mao; Jing Feng; Ceshi Chen
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

10.  Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis.

Authors:  Haihao Wang; Ji Ke; Qiannan Guo; Kan-Paatib Barnabo Nampoukime; Peiwen Yang; Ke Ma
Journal:  J Cell Mol Med       Date:  2018-09-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.